Azitra, Inc. (AZTR)
Market Cap | 7.85M |
Revenue (ttm) | 572,700 |
Net Income (ttm) | -12.40M |
Shares Out | 7.63M |
EPS (ttm) | 24.00 |
PE Ratio | 0.04 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,137,868 |
Open | 1.140 |
Previous Close | 1.140 |
Day's Range | 1.010 - 1.150 |
52-Week Range | 1.010 - 118.500 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 12, 2024 |
About AZTR
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR... [Read more]
Financial Performance
In 2023, Azitra's revenue was $686,000, an increase of 141.55% compared to the previous year's $284,000. Losses were -$12.64 million, -6.02% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/8/x/press8-2547048.jpg)
CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION ...
![](https://cdn.snapi.dev/images/v1/4/y/press6-2546247.jpg)
You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing
PALO ALTO, Calif.--(BUSINESS WIRE)--You.com, the AI-powered productivity engine, today announced a new strategic collaboration with Moesif, a leading provider of monetization and usage-based billing f...
![](https://cdn.snapi.dev/images/v1/g/k/press14-2546252.jpg)
Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities
TUSTIN, Calif.--(BUSINESS WIRE)--Wingspire Equipment Finance is proud to announce a $12,000,000 equipment financing to a leading aerospace manufacturing company. The Tier 1 aerospace manufacturer is k...
![](https://cdn.snapi.dev/images/v1/x/r/press8-2540999.jpg)
Azitra, Inc. Announces Pricing of $10.0 Million Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
![](https://cdn.snapi.dev/images/v1/l/u/press19-2538985.jpg)
Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
![](https://cdn.snapi.dev/images/v1/u/g/press17-2500951.jpg)
Azitra, Inc. Announces Reverse Stock Split
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
![](https://cdn.snapi.dev/images/v1/n/j/press17-2455946.jpg)
Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
![](https://cdn.snapi.dev/images/v1/y/q/press15-2436918.jpg)
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
![](https://cdn.snapi.dev/images/v1/v/b/press13-2423889.jpg)
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
![](https://cdn.snapi.dev/images/v1/i/c/press12-2422911.jpg)
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
![](https://cdn.snapi.dev/images/v1/o/m/press2-2384224.jpg)
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
![](https://cdn.snapi.dev/images/v1/v/p/conf17-2379472.jpg)
Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced i...
![](https://cdn.snapi.dev/images/v1/u/c/press10-2327227.jpg)
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
![](https://cdn.snapi.dev/images/v1/s/d/press3-2281081.jpg)
Azitra, Inc. Announces Closing of Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, t...
![](https://cdn.snapi.dev/images/v1/z/2/press4-2275011.jpg)
Azitra, Inc. Announces Pricing of Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
![](https://cdn.snapi.dev/images/v1/q/q/press9-2230687.jpg)
Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
![](https://cdn.snapi.dev/images/v1/l/3/conf11-2214772.jpg)
Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
![](https://cdn.snapi.dev/images/v1/w/s/press5-2158154.jpg)
Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
![](https://cdn.snapi.dev/images/v1/o/m/conf17-2104359.jpg)
Azitra to Present at the ThinkEquity Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today t...
![](https://cdn.snapi.dev/images/v1/m/g/conf13-2040980.jpg)
Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRANFORD, Conn., Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, anno...
![](https://cdn.snapi.dev/images/v1/f/2/press2-2022408.jpg)
Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
![](https://cdn.snapi.dev/images/v1/o/i/press5-1978985.jpg)
Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors
BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
![](https://cdn.snapi.dev/images/v1/b/g/press5-1966957.jpg)
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer
BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
![](https://cdn.snapi.dev/images/v1/e/e/press5-1943361.jpg)
Azitra, Inc. Announces Closing of Initial Public Offering
BRANFORD, Conn. , June 21, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...
![](https://cdn.snapi.dev/images/v1/r/0/press16-1936848.jpg)
Azitra, Inc. Announces Pricing of Initial Public Offering
BRANFORD, Conn. , June 15, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...